ERBB2 and breast cancer: However, after endocrine treatment, ESR1, ERBB2, NF1, EGFR and MYC variants were significantly increased in FFPE tissue of HR-positive BC patients in the MSK-IMPACT study [200] with ESR1 variants presenting in a prevalence of 20–50% [275,276].